

Medication Adherence Hypertension BCBSAL

© Copyright IBM Corporation 2018

MEASURE DESCRIPTION:

This measure is defined as the percent of members ages 18 or older who adhere to their prescribed drug therapy for renin angiotensin system (RAS) antagonists (angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB) or direct renin inhibitor medications).

PROPRIETARY STATUS: This measure is owned by Truven Health Analytics Inc.

REVISION CRITERIA: This measure is based on the PQA® Medication Adherence Measures used in the CMS Star Rating program for Medicare Advantage plans.

MEASURE PACKAGE:

MINIMUM DATA REQUIREMENTS (months): 24

MEASURE DETAILS:

DENOMINATOR:

Members ages 18 years and older as of 6 months before the start of the measurement period, who have at least two fills of an anti-hypertensive medication during the measurement year. To be included in the measure, members must also have a qualifying anti-hypertensive prescription at least 90 days prior to the start of the measurement period.

Two scripts for an anti-hypertensive medication during the measurement year	For full list of NDC codes, reference: PQA RASA Medication list dated April 2018
AND At least one script for an anti-hypertensive medication at least 90 days before the start of the measurement year	
AND	
Age (6 months prior to measurement year)	Age in Years >= 18

EXCLUSIONS:

Patients with ESRD during the measurement period or who had one or more prescriptions for Sacubitril/Valsartan during the measurement year are excluded.

ESRD during the measurement year	ICD-9 Diagnosis Code = 585.5, 585.6, V45.11, V4512
	OR
	ICD10 Diagnosis Code = N18.5, N18.6, Z91.15, Z99.2
	OR
	Procedure Code = 36147, 36800, 36810, 36815, 36818, 36819, 36820, 36821, 36831, 36832, 36833, 90935, 90937, 90940, 90945, 90947, 90951, 90993, 90997, 90999, 99512, G0257, S9339
	OR
	ICD-9 Procedure Code = 38.95, 39.27, 39.42, 39.43, 39.93, 39.94, 39.95, 54.98
	OR
	ICD-10 Procedure Code = 3E1M39Z, 5A1D00Z, 5A1D60Z
	OR
Revenue Code = 800-804, 809, 820-825, 829-835, 839-845, 849-855, 859, 880 - 882, 889	
OR	
Type of Bill = 720-725, 727, 728, 072A, 072B, 072C, 072D, 072E, 072F, 072G, 072H, 072I, 072J, 072K, 072M, 072O, 072X, 072Y, 072Z	
OR	
POS = 65	
OR	
One or more prescriptions for Sacubitril/Valsartan during the measurement year	Reference List: PQA Medication list for RASA Sacubitril/Valsartan

NUMERATOR:

Members with at least 270 days supply of a qualifying blood pressure medication during the measurement year. Qualifying "Blood pressure medication" includes an ACE (angiotensin converting enzyme) inhibitor, an ARB (angiotensin receptor blocker), or a direct renin inhibitor drug.

Days Supply >= 270 during the measurement year	For full list of NDC codes, reference: 2019 NDC PQA PDC RASA Drugs dated October 2019
--	--

CONTINUOUS ENROLLMENT:

Continuously enrolled with medical coverage during the measurement year, which equates to 12 months out of 12 months, with an allowable gap of 45 days. Member must be enrolled on measurement period end date (anchor date).

MEASURE BACKGROUND:

The National Health and Nutrition Examination Survey (NHANES) found the prevalence of hypertension in the U.S. adult population to be 29 percent in 2007-2008.

COPYRIGHTS AND ACKNOWLEDGEMENTS

© Copyright IBM Corporation 2019

The measure specification methodology used by the IBM Corporation 2019 is different than NCQA's methodology. NCQA has not validated the altered measure specifications but has granted IBM Corporation 2019 permission to modify as needed.

None of the measures produced from quality rules engine (QME) have been validated by NCQA. NCQA specifications provided in QME are for reference only and are not an indication of measure validity produced by QRE. A measurement rate does not constitute a HEDIS rate unless it audited and approved by an NCQA-certified HEDIS Compliance Auditor. All measurement rates produced by QRE shall not be designated or referenced as a HEDIS rate or HEDIS result for any purpose.

Terms of Use

The recipient of these documents shall treat the information contained herein as confidential, proprietary information, owned by IBM Corporation 2019. The recipient shall not disclose or permit to be disclosed, in whole or in part, to any third party any information contained herein.

No part of these documents may be reproduced, translated, or transmitted in any form, by Photostat, microfilm, xerography, recording or any other means, or stored or incorporated into any information retrieval system, electronic or mechanical, without the prior written permission of the copyright owner.

The software, data, and other information to which this publication relates have been provided under the terms of a License Agreement with IBM Corporation 2019.

NCQA Notice of Use. The HEDIS® measures and specifications were developed by and are owned by the National Committee for Quality Assurance (“NCQA”). The HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. NCQA holds a copyright in these materials and can rescind or alter these materials at any time. These materials may not be modified by anyone other than NCQA. All uses, including reproduction, distribution, publication must be approved by NCQA and are subject to a license at the discretion of NCQA.

© 2019 NCQA, all rights reserved. Limited proprietary coding is contained in the measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. The American Medical Association holds a copyright to the CPT® codes contained in the measure’s specifications. The American Hospital Association holds a copyright to the Uniform Bill Codes (“UB”) contained in the measure specifications. The UB Codes in the HEDIS specifications are included with the permission of the AHA. The UB Codes contained in the HEDIS specifications may be used by health plans and other health care delivery organizations for calculating and reporting HEDIS measure results or using HEDIS measure results for their internal quality improvement purposes. All other uses of the UB Codes require a license from the AHA. Anyone desiring to use the UB Codes in a commercial product to generate HEDIS results, or for any other commercial use, must obtain a commercial use license directly from the AHA. To inquire about licensing, contact ub04@healthforum.com.

© 2019 National Committee for Quality Assurance. All rights reserved.

CPT® copyright 2018 American Medical Association. All rights reserved. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Applicable FARS/DFARS restrictions apply to government use. CPT is a registered trademark of the American Medical Association.

The LOINC® codes, LOINC® table (regardless of format), LOINC® Release Notes, LOINC® Changes File, and LOINC® Users’ Guide are copyright © 1995-2019, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. All rights reserved.

REDBOOK™ is a trademark of IBM Corporation 2019.

The National Drug Code (NDC) Directory is published by the U.S. Food and Drug Administration and is made available under the Open Database License: <http://opendatacommons.org/licenses/odbl/1.0/>. Any rights in individual contents of the database are licensed under the Database Contents License: <http://opendatacommons.org/licenses/dbcl/1.0/>.

The International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) is published by the World Health Organization (WHO). ICD-9-CM is an official Health Insurance Portability and Accountability Act standard.

The International Classification of Diseases, 9th Revision, Procedure Coding System (ICD-9-PCS) is published by the World Health Organization (WHO). ICD-9-PCS is an official Health Insurance Portability and Accountability Act standard.

The International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) is published by the World Health Organization (WHO). ICD-10-CM is an official Health Insurance Portability and Accountability Act standard.

AMA PCPI Notice of Use. Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement (the Consortium), are intended to facilitate quality improvement activities by physicians. These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures. The Measures are provided as is without warranty of any kind. ©2019 American Medical Association. All Rights Reserved. UB-04 Manual.

OFFICIAL UB-04 DATA SPECIFICATIONS MANUAL, 2017, is protected under federal copyright laws and owned by the **American Hospital Association (“AHA”)**, Chicago, Illinois. No portion of the OFFICIAL UB-04 MANUAL may be reproduced, sorted in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior express, written consent of AHA.

This measure is proprietary and owned by IBM Corporation 2019. It is provided under the terms of a License Agreement with IBM Corporation 2019.